Assembly Biosciences (ASMB) shares were higher Wednesday morning after the company said that a first subject has been dosed in the phase 1a trial of ABI-6250, its hepatitis delta virus entry inhibitor candidate.
The study aims to evaluate the safety, tolerability and pharmacokinetics of the therapy across single and multiple ascending dose cohorts in participants. The study will also look at serum bile acids as a biomarker of ABI-6250's engagement of its target, which is the transporter used by the disease to infect hepatocyte.
The company said it expects to share data from the study in Q3.
Price: 12.90, Change: +0.56, Percent Change: +4.54
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.